GeneDx Valuation Multiples

GeneDx Overview

About GeneDx

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Founded

2000

HQ

Employees

1.3K

Website

genedx.com

Sectors

Diagnostics & GenomicsHealth Data & AnalyticsDeepTechHealthTech

Financials (LTM)

Revenue: $464M

EBITDA: $37M

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

GeneDx Financials

GeneDx reported last 12-month revenue of $464M and EBITDA of $37M.

In the same LTM period, GeneDx generated $327M in gross profit, $37M in EBITDA, and $37M in net income.

GeneDx P&L

In the most recent fiscal year, GeneDx reported revenue of $428M and EBITDA of $40M.

GeneDx expects next 12-month revenue of XXX and NTM EBITDA of XXX

GeneDx Stock Performance

GeneDx has current market cap of $2B, and enterprise value of $2B.

GeneDx's stock price is $66.00.

GeneDx Valuation Multiples

GeneDx trades at 4.0x EV/Revenue multiple, and 51.2x EV/EBITDA.

GeneDx Financial Valuation Multiples

As of April 19, 2026, GeneDx has market cap of $2B and EV of $2B.

Equity research analysts estimate GeneDx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

GeneDx has a P/E ratio of 52.5x.

GeneDx Margins & Growth Rates

GeneDx's revenue in the last 12 month grew by 28%.

GeneDx's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

GeneDx's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

GeneDx's rule of X is 77% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

GeneDx Public Comps

See public comps and valuation multiples for other Diagnostics & Genomics and Health Data & Analytics comps.

GeneDx M&A Activity

GeneDx acquired XXX companies to date.

Last acquisition by GeneDx was on XXXXXXXX, XXXXX. GeneDx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

GeneDx Investment Activity

GeneDx invested in XXX companies to date.

GeneDx made its latest investment on XXXXXXXX, XXXXX. GeneDx invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).